Nikhil C. Munshi, MD - The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes

Go online to PeerView.com/KTZ860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Are you fully prepared to safely integrate BCMA-targeting
options into the care plan for your relapsed/refractory multiple
myeloma (MM) patients, including treatment with antibodies,
bispecific agents, and CAR-T cell therapy? Find out in this
expert-led MasterClass and Case Forum recorded at the Annual
Hematology Meeting. Watch our experts as they offer learners
guidance on the “road to remission” in MM, and hear how recent
advances with BCMA-targeted therapies can directly lead to enhanced
outcomes in the most challenging treatment settings. Throughout,
the experts also provide case-based guidance on therapy selection
with BCMA antibodies and CAR-T therapy, and illustrate how
evidence-based practice can optimize delivery of care in pretreated
disease. Get on the “road to remission” for your patients, and
receive CME/MOC credit today! Upon completion of this activity,
participants should be better able to: State the current evidence
and rationale that support the treatment roles of novel
BCMA-targeting platforms, including antibody-drug conjugates,
bispecifics, and CAR-T therapy, in relapsed/refractory disease;
Select personalized, evidence-based regimens with novel anti-BCMA
options based on patient preference, disease prognosis, and
functional status, among others; and Develop strategies for
addressing practical aspects of BCMA-targeted therapy in RRMM,
including issues related to dosing/scheduling, patient counseling,
and unique safety considerations such as cytopenias,
infusion-related events, ocular toxicity, and cytokine release
syndrome, among others.